EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Circulating Tumour DNA in Patients With EGFR ‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study

Akihiro Tamiya iD, Yasuyuki Mizumori, Mitsuo Osuga, Shun-Ichi Isa, Yoshihiko Taniguchi, Keiichi Nakamura, Daijiro Harada, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori und 5 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70861 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Akihiro Tamiya und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca KK, National Hospital Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib is the standard therapy for patients with chemotherapy‐naive advanced non‐small‐cell lung cancer (NSCLC) harbouring sensitising epidermal growth factor receptor ( EGFR ) mutations. However, some patients treated with osimertinib experience progressive disease (PD). Therefore, this study aimed to explore mechanisms underlying osimertinib resistance, focusing on early PD (within 6 months).

Methods

This multicentre prospective observational study enrolled patients with advanced NSCLC receiving osimertinib as the first‐line anti‐cancer therapy. Mutations in cancer‐associated genes were analysed using next‐generation sequencing of circulating tumour DNA samples collected before osimertinib treatment and on detection of PD.

Findings

Between May 2019 and January 2021, 188 patients were enrolled, of whom 125 (66%) were women and 96 (51%) had EGFR exon 19 deletion mutations. In this interim analysis, 78 patients experienced PD and 36 experienced early PD. Compared with patients without early PD, those with early PD were more likely to test positive for EGFR ‐activating mutations at baseline (86.1% vs. 63.4%, p = 0.009) and had significantly more co‐occurring gene mutations in addition to EGFR mutations (2.89 ± 1.49 vs. 1.97 ± 1.37, p = 0.002). In three patients with early PD, one patient each had a germline BRCA1 , BRCA2 and BRINP3 mutation.

Conclusion

EGFR mutations in ctDNA and multiple co‐occurring gene mutations at baseline are associated with poor outcomes and early PD. Plasma‐based serial comprehensive gene profiling could help predict and identify patients who are unlikely to benefit from osimertinib treatment. Trial Registration: Japanese Register of Clinical Trials JRCT: registration number: jRCTs031180051

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesAniline CompoundsCirculating Tumor DNAAntineoplastic AgentsHumansFemaleMaleErbB ReceptorsMiddle AgedAgedProspective StudiesMutationDisease ProgressionAdultDrug Resistance, NeoplasmAged, 80 and overBiomarkers, TumorIndolesPyrimidines

Stichwörter der Autor:innen

EGFR mutationscirculating tumour DNAnext‐generation sequencingnon‐small‐cell lung cancerosimertinibresistance mechanisms

Substanzen

osimertinibErbB ReceptorsEGFR protein, humanAcrylamidesAniline CompoundsCirculating Tumor DNABiomarkers, TumorAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan.
  • Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
  • Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan.
  • Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.

ORCID-Profile: Akihiro Tamiya, Atsuhisa Tamura, Yasuhiro Koh

Förderung

  • AstraZeneca KK
  • National Hospital Organization

Zitieren

APA

Tamiya, A., Mizumori, Y., Osuga, M., Isa, S. I., Taniguchi, Y., Nakamura, K., Harada, D., Shinohara, T., Yanai, H., Nakatomi, K., Oki, M., Mori, M., Kuwako, T., Yamazaki, K., Tamura, A., Ando, M., & Koh, Y. (2025). Circulating Tumour DNA in Patients With EGFR ‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study. Cancer Medicine. https://doi.org/10.1002/cam4.70861

Vancouver

Tamiya A, Mizumori Y, Osuga M, Isa SI, Taniguchi Y, Nakamura K, et al. Circulating Tumour DNA in Patients With EGFR ‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study. Cancer Medicine. 2025. doi:10.1002/cam4.70861

BibTeX
@article{Tamiya2025,
  author = {Tamiya, Akihiro and Mizumori, Yasuyuki and Osuga, Mitsuo and Isa, Shun-Ichi and Taniguchi, Yoshihiko and Nakamura, Keiichi and Harada, Daijiro and Shinohara, Tsutomu and Yanai, Hidetoshi and Nakatomi, Katsumi and Oki, Masahide and Mori, Masahide and Kuwako, Tomohito and Yamazaki, Koji and Tamura, Atsuhisa and Ando, Masahiko and Koh, Yasuhiro},
  title = {Circulating Tumour DNA in Patients With EGFR ‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70861}
}
Kostenlos starten →